Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | PALB2 |
Variant | P1009Lfs*6 |
Impact List | frameshift |
Protein Effect | loss of function |
Gene Variant Descriptions | PALB2 P1009Lfs*6 indicates a shift in the reading frame starting at amino acid 1009 and terminating 6 residues downstream causing a premature truncation of the 1186 amino acid Palb2 protein (UniProt.org). P1009Lfs*6 confers a loss of function to the Palb2 protein as demonstrated by decreased protein stability and impaired homology-directed DNA repair activity compared to wild-type in cultured cells lacking Tp53 (PMID: 31757951). |
Associated Drug Resistance | |
Category Variants Paths |
PALB2 mutant PALB2 inact mut PALB2 P1009Lfs*6 |
Transcript | NM_024675.4 |
gDNA | chr16:g.23621453delG |
cDNA | c.3026delC |
Protein | p.P1009Lfs*6 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_024675.3 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
XM_017023673 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
XM_017023672.2 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
XM_017023673.2 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
NM_001407301.1 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
NM_024675.4 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
NM_001407299.1 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
XM_017023672 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
NM_024675 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PALB2 P1009Lfs*6 | Advanced Solid Tumor | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lynparza (olaparib) resulted in decreased survival of TP53-knockout cells expressing PALB2 P1009Lfs*6 in culture (PMID: 31757951). | 31757951 |